ELA elimination final rule drops "well characterized" definition; FDA expands list of eligible biologics.
Executive Summary
FDA BROADENS LIST OF NON-ELA BIOLOGICAL PRODUCT CATEGORIES in a final rule eliminating the requirement for establishment licensing applications for certain biologics published in the Federal Register May 14. The rule eliminates ELA requirements for therapeutic DNA plasmid products, therapeutic synthetic peptide products of 40 or fewer amino acids, monoclonal antibody products for in vivo use and therapeutic recombinant DNA-derived products.
You may also be interested in...
Biologics Applicants Are Responsible For Contract Facility Compliance - FDA
Biologics license applicants will be held responsible for contractor deviations from cGMPs, FDA says in an updated draft "Guidance for Industry: Cooperative Manufacturing Arrangements for Licensed Biologics."
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011